Amgen braces for biosimilars rules

You are here: Home > Banking & Finance > Current Article

By Stephen Nellis / Friday, October 7th, 2011 / Comments Off on Amgen braces for biosimilars rules

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

The U.S. Food and Drug Administration is set to release guidelines for biosimilar drugs by year’s end. The shape of those guidelines will determine whether the new drugs are a competitive threat or a potential market opportunity for Amgen, the world’s largest biotechnology firm and the biggest private-sector employer in Ventura County. Biosimilars are the…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.